HIV Vaccine and Antibody Efficacy Trials to Date

This infographic provides a comprehensive overview of HIV vaccine and antibody efficacy trials. Over 20 years and 12 trials, only two positive signals have been observed.

Avac Event

AVAC in Conversation with NIAID’s Jeanne Marrazzo

The new director of National Institute of Allergy and Infectious Diseases (NIAID), Dr. Jeanne Marrazzo joined AVAC Executive Director in conversation.

The HIV Prevention Pipeline

This graphic shows currently available options for HIV prevention, newly approved and recommended treatment, and those in development.

Px Wire September 2023

Volume 13, Number 3

Avac Event

ICASA 2023

Join AVAC and partners for the biennial International Conference on AIDS and Sexually Transmitted Infections (ICASA), in Harare, Zimbabwe December 4-9. More than 30 of our partners will convene at the meeting to champion community leadership and amplify their role in shaping local, national and global responses and delivering impactful advocacy. Community leadership on a range of issues are instrumental to: 

  • Accelerate and expand access to proven prevention options that people want and need. 
  • Dismantle the structural barriers to health faced by key populations. 
  • Intensify demands for robust domestic and global funding for health. 
  • Integrate HIV services with sexual and reproductive health. 
  • And much more. 

Scroll down for a roadmap to ICASA’s prevention program, and details on sessions and events that you won’t want to miss. 

Sessions of Interest

Sunday, December 3

  • Biomedical Prevention Forum 
    9:00-15:00 GMT 
    The Biomedical Prevention Forum will be held as a hybrid event bringing together advocates, civil society representatives, researchers, government officials and front-line providers to explore and discuss the latest advancements, challenges, and opportunities in biomedical HIV prevention, while emphasizing the importance of choice and its transformative impact on HIV prevention efforts. This is an open event. Register here. 
  • Key Populations Preconference 
    9:00-15:00 GMT 
    The Africa Key Populations Experts Group (AKPEG), African Sex Workers Alliance (ASWA), the African Network of People Using Drugs (AfricanPUD) and African Queer Youth Initiative (AQYI) Advocates for Prevention of HIV and AIDS in Africa (APHA), Global Black Gay Men Connect (GBGMC) and partners will host a safe platform to deliberate on the state of the HIV epidemic among Key Populations and to determine the stumbling blocks for progress on the path that ends AIDS for Key Populations.

Monday, December 4

Tuesday, December 5

  • Advancing Integrated Biomedical Prevention: Best Practices from Zimbabwe (Session 2) 
    8:45-09:30 GMT
    This satellite session will discuss best practices and lessons learned from the delivery of biomedical HIV prevention and Voluntary Medical Male Circumcision services as we work to further universal health coverage and robust health systems. Partners will launch a global call to action to unite, mobilize, and advocate for continued prioritized funding, sustained commitment, and strategic integration of VMMC into national and global prevention strategies.
  • Catalyzing a sustainable HIV prevention agenda: Approaches to expand local action on global commitments
    10:45-11:30 GMT
    Leveraging new strategic plans for HIV prevention, including the PEPFAR’s 5-year Strategy and UNAIDS’ Prevention Road Map, this satellite session will discuss combination prevention in the context of a sustainable HIV response and highlight a variety of approaches and models that leverage country and stakeholder-led innovations to meet the challenge.
  • Coordinating Implementation Science for CAB for PrEP: BioPIC’s Implementation Study Tracker 
    12:25-12:35 GMT
    In this oral abstract session, AVAC will present a new dashboard, which reflects all currently known activities relating to implementation research, modelling, clinical research, and landscaping for new late-stage biomedical HIV PrEP options, including cabotegravir for PrEP and the dapivirine vaginal ring.
  • Policy, Politics and HIV Management 
    13:05-13:50 GMT
    In this oral abstract session, Princess Mharire from Pangaea Zimbabwe AIDS Trust (PZAT) will present, Beyond Metrics: How the Simple Participatory Assessment of Real Change (SPARC) Tool Provides a Holistic Approach to Advocacy Measurement, and Joseph Njowa of PZAT will share the COMPASS MERL model in a presentation, Innovative tools for planning, monitoring, and evaluation of advocacy campaigns. 

Wednesday, December 7

Friday, December 8

  • Strengthen integration for better SRHR outcomes 
    10:45-11:30 GMT
    This concurrent session will feature Advocates for Prevention of HIV and AIDS in Africa’s (APHA) Yvette Raphael and will explore linkages between unintended pregnancies, unsafe abortion, and HIV.
  • HIV Prevention-Right Place, Right time 
    13:05-13:50 GMT
    This concurrent session will feature Maureen Luba of AVAC, Definate Nhamo of PZAT and Yvette Raphael of APHA. 

AVAC and Partner Poster Presentations

Tuesday, December 5 

  • Maximizing private pharmacies for PrEP delivery to increase uptake: Lessons learnt from the Community Retail Pharmacy Distribution Point, Ruth Akulu 

Wednesday, December 6 

  • Journalist Training: A Key Advocacy Strategy, Catherine Madebe
  • Perceptions on the new biomedical HIV prevention methods among adolescent girls and young women in tertiary institutions in Zimbabwe, Cleo Makura
  • Lessons from Crisis Response from TaNPUD in Enhancing Harm Reduction from 2015 to 2018, Marineus Mutongore
  • Implementing Community led Monitoring for improved quality of HIV services in Tanzania, Mathew Kawogo
  • Impact of social media exposure on HIV services uptake among Tanzanian Young people: Implications for enhancing the HIV response, Marineus Mutongore
  • Effective Strategies for Operating COWLHA support groups of Adolescents Living with HIV: Case of Mangochi and Chikwawa Districts of Malawi, Harry Madukani

Thursday, December 7 

  • Understanding Choice of HIV Prevention Options among Adolescent Girls and Young Women (AGYW) in Zambia, Natasha Mwila
  • Leveraging HIV to Build a Global Health Research and Development (R&D) Equity Advocacy Agenda, John Meade
  • Championing advocacy for domestic resource mobilization for health research and development in Africa, Ethel Makila

Friday, December 8 

  • Rural Youth: Underserved and Unsafe When Seeking Care, Liyema Somnono
  • Redefining Coalition Governance and Leadership in Support of Decolonizing Global Health: The Evolution of the COMPASS Coalition, Roberta Sutton
  • Collaborative Monitoring & Evaluation to Support Learning and Strengthen Advocacy Coalitions: The MERL Hub, Grace Tetteh
  • Realities faced by street children predisposing them to HIV and STIs in Dodoma and Dar es Salaam Cities in Tanzania, Simon Shilagwa 

HIV-Specific Neutralizing Antibodies by Target

A number of broadly neutralizing antibodies that target various regions of HIV’s Env protein are being developed for HIV prevention.

Experimental Medicine Vaccine Trials (EMVTs): Opportunities and Challenges

In 2023, AVAC and CASPR partners cast a spotlight on many issues and opportunities for HIV vaccine science. This one-pager highlights key conversations.

Avac Event

IAS (International AIDS Society) 2023

The 12th annual conference of the International AIDS Society (IAS) on HIV science takes place July 23–26 in Brisbane, Australia, and virtually. This year’s conference will offer the latest on vaccine and cure science, research updates on broadly neutralizing antibodies, important discussions on trial design in the era of PrEP, the potential of community-led models of care and the importance of integrating services for HIV and sexual and reproductive health (SRH). AVAC and partners will be there! Read on for an overview.

Just ahead of the conference, UNAIDS released their annual state of the epidemic report, The Path that Ends AIDS. The report charts a path that can end AIDS, and documents important progress, but challenges remain. Among them, global resources for HIV are marking another year of decline. With anti-LGTBQIA+ legal actions increasing in the US and in several African countries and reduced resources, efforts to end the epidemic will fail. See AVAC’s new graphic on the issue.

IAS Resources

  • Use AVAC’s Roadmap to find sessions where prevention, pandemic preparedness and the larger issues of global health equity are in the spotlight. You can download it as a sortable spreadsheet or PDF.
  • Follow events in real time, AVAC will offer comments and updates on Twitter, and our friends at NAM/AIDSMAP will be reporting throughout the conference. Join the conversation using the conference hashtag #IAS2023.

Satellites, Sessions and Panels Featuring AVAC and Partners

All times listed are local in Brisbane, Australia. Click for a time zone converter.

Sunday, July 23

Tuesday, July 25

Wednesday, July 26

Poster Presentations

  • No Data No More: A tool to end the exclusion of trans and gender-diverse people in HIV research
  • Raising New Voices in HIV Cure Research: A review of an advocacy-for-cure academy and grant program
  • The Value of Measuring Outcomes of HIV Advocacy: Utilising a novel and participatory approach for advocacy evaluation
  • HIV Prevention Research & Development Investments 2001-2021: Shifting investment priorities fund innovation in a challenging global health landscape
  • Revolution of Transgender Health Programming: The role of transgender activists in Health programming for Malawi

While many will be gathering in Australia for the IAS conference, the 27th International Society for Sexually Transmitted Diseases Research (ISSTDR)is happening in Chicago at the same time – and AVAC will be there, too. Stay tuned for an update later this week for AVAC’s STI Roadmap and dedicated STI conference page. Advocates, implementers and researchers in both fields have much work to do together.

Antibody Related Research

Increasing focus on broadly neutralizing antibodies

The Years Ahead in Biomedical HIV Prevention Research

This graphic shows the updated status of large-scale prevention trials through 2024.